EXHIBIT A

ATTORNEY DOCKET NO. 07030.0004U2 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Borberg, et al.) Art Unit: 3761
Application No. 10/649,968	Examiner: Wiest, Philip R
Filing Date: August 26, 2003	Confirmation No. 7077
FOI: METHOD FOR TREATMENT DISEASES ASSOCIATED WITH A DETERIORATION OF THE MACROCIRCULATION, MICROCIRCULATION, AND ORGAN PERFUSION	

DECLARATION UNDER 37 C.F.R. § 1.132

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C. Customer Number 23859

Sir:

- I, Helmut Borberg, hereby declare that:
- 1. I am Professor of Medicine at the University of Koeln, Germany, and hold a M.D. in Medicine from the University of Muenster Germany and an honourable academic degree (doctor honoris causa) in Medicine from the University of Budapest, Hungary. I was trained in Immunohaematology at the New York University Medical School, Department of Immunology and subsequently in Tumorimmunology at the Sloan Kettering Institute, Department of Immunology, Cornell University Division, New York. Heading the Division of Hemapheresis and Tumorimmunology and acting as the Director of the German Hemapheresis Center I have over over 47 years experience in the field of Apheresis with an emphasis on apheresis

781955

ATTORNEY DOCKET NO. 07030.0004U2 Application No. 10/649,968

technologies and over 47 years experience in the study of Internal Medicine and Transfusion Medicine. This includes specific experience in the development of cell separation techniques, blood transfusion and apheresis treatments A partial curriculum vitae is attached to this declaration as an exhibit.

- 2. I have reviewed the specification of the above-identified application.
- 3. I have reviewed the Office Action mailed October 22, 2008 in connection with the above-identified application and the following references cited in that Office Action:
 - a) Georgadze et al (Vestn Khir Im II Grek 142(3):20-24. 1989), cited as allegedly disclosing plasmapheresis may be used for the treatment of ischemia in the lower extremities of diabetics:
 - U.S. Patent 4,350,156 by Malchesky et al, cited as allegedly disclosing plasmafiltration of blood for the removal of high molecular weight protein; and
 - U.S. Patent 5,152,979 by Hunter, cited as allegedly disclosing that ischemia causes increased viscosity of blood and recognizes that increased whole blood viscosity is capable of causing serious circulatory disturbances;
- 4. 1 understand that claims 1 and 2 of the above referenced application have been rejected under 35 U.S.C. § 103(a) as being unpatentable over Georgadze et al, in view of Malchesky et al, and further in view of Hunter. Specifically, I understand that the rejection is based in part on the contention that it would have allegedly been obvious to one at the time the present application was filed to modify the method of Georgadze et al. to specifically remove high molecular weight protein, such as lipoprotein cholesterol, as allegedly taught by Malchesky et al. since both allegedly teach removal of protein from the blood to achieve a therapeutic result, such as returning blood to its normal viscosity, and Hunter allegedly teaches that ischemia causes

ATTORNEY DOCKET NO. 07030.0004U2 Application No. 10/649.968

impaired circulation because of blood hyperviscosity. I present in this declaration evidence to the contrary. For example, the evidence indicates that:

- a) at the time the application was filed, the skilled artisan reading Georgadze et al.,
 Malchesky et al. and Hunter would not have been motivated to remove high molecular weight proteins from the blood to treat diabetic ischemia;
- even if attempted, there would have been no reasonable expectation of success that removal of high molecular weight protein from the blood would have been effective at treating diabetic ischemia; and
- the scientific community has recognized the success of the claimed approach since the publication by the inventor.
- 5. I declare that neither Georgadze nor Malchesky nor Hunter have presented specific data or evidence on the research of hemorheology to explain the clinical efficacy of the healing of diabetes feet applying extracorporeal hemorheotherapy (rheopheresis, rheohemapheresis).
- 6. I declare that that the same treatment technology was applied and accepted as US patents for the treatment of ophthalmological diseases and small vessel disease and other diseases.

I declare that all statements made herein of my own knowledge and belief are true and that all statements made on information and belief are believed to be true, and further, that the statements are made with the knowledge that willful false statements are punishable by fine or

ATTORNEY DOCKET NO. 07030.0004U2 Application No. 10/649,968

imprisonment, or both, under section 1001 of	Fitle 18 of the United States Code, and that such
willful false statements may jeopardize the val	idity of the application or any patent issuing
thereon.	1 (
Date: April 18 th , 2008	Helmut Borberg, MD, Professor of Modicine

CURRICULUM VITAE

PROF.Dr.med.Dr.med.h.c. HELMUT BORBERG UNIVERSITY OF KÖLN, GERMANY

BIRTHDAY Mai 6th, 1934

BIRTHPLACE Lippstadt (Westphalia), Germany

MARITAL STATUS Married March 3rd, 1976

CHILDREN Three children

SCHOOL TRAINING Grammar school and German Gymnasium

until 1955

PROFESSIONAL TRAINING Medical schools of the universities of

Marburg, München and Münster

GRADUATION (PROMOTION) M.D. (Dr. med.), University of Münster 1961

RESEARCH TRAINING Electron microscopy, Department of Pathology, University of Munster and Department of Dermatology, University of Frei-

burg, 1964

Immunohaematology 1965 - 1966 New York University Medical School, Division of Haematology (Head:P.A.Miescher,MD, Prof.of Medicine)

Tumorimmunology 1966 - 1969

Sloan-Kettering Institute for Cancer Research, Division of Tumorimmunology, (Head: L.J.Old,MD,PhD,Prof.of.Immunology)

CLINICAL TRAINING Basic training at different hospitals

and universities in Germany, 1961 - 1965

Internal medicine, University of Köln

1969 - 1975

Haematology - Oncology 1975 - 1982

HABILITATION (2nd Thesis) June 16th, 1982

PROFESSORSHIP November 24th, 1988

POSITIONS

UNIVERSITY OF KÖLN 1969 - 1999

Associate Professor of Medicine

Head, Haemapheresis Unit, Department

of Internal Medicine

Head, Tumorimmunology, Department

of Internal Medicine

1999 Retirement

PRESENT Professor of Medicine (em.), University of

Köln Germany

Director, German Haemapheresis Centre

Köln, Germany

HONORARY 1987 Congress President, Annual Congress

of the European Society for Haemapheresis,

President, European Society for Haemaphere sis, 1987 - 1989

Head, Board of the first Apheresis Commission of the German Society for Blood Trans

Treasurer, European Society for Haemphere-

sis, since 1997

fusion 1988

AWARDS Ludwig Heilmeyer Award

(German Society for the Advancement of

Internal Medicine)

Honorary Graduation University of Budapest, Hungary (Dr. med. h. c.)

Cobe Award (German Society of Transfusion Medicine and Immunohaematology)

ESFH Senior Investigator Award (European

Society for Haemapheresis)

SCIENTIFIC PUBLICATIONS

Approximately 180 publications on investigational topics in tumorimmunology, internal medicine, haematology and haemapheresis

MEMBERSHIPS

German Society for Internal Medicine
German Society for Blood Transfusion and Immunohaematology
German Cancer Society
German Society for Haematology and Oncology
German Society for Immunology
European Society for Haemapheresis
International Society of Blood Transfusion
German Society of Rheelogy

(Past) Editorial and Advisory Board Memberships Journal of Transfusion Medicine and Hemotherapy Journal of Transfusion Science and Apheresis Therapy

Consultant, Societa d'Hemaferesi Italiano